Pathelen contains a unique patented formula, which when shaken for 15-20 seconds, will grow visibly in density by more then 20 times, creating the advanced sorption property and filling the bottle content.
*Pathelen Woundpowder and Pathelen Hybrid are the same product.
Pathelen® is a Class I medical device, specifically designed and developed for the treatment of multi-resistant bacteria (such as MRSA) in open wounds. Vitally, bacteria are unable to develop resistance to it, in contrast to all antibiotics designed to perform a similar function.
Pathelen® eliminates most external bacterial wound infections within 5-10 days in most cases such as preparing for a wound closure surgery or enhancing the growth of granulating tissue on the treated wound.
It has a wide range of antimicrobial uses, highly effective in combating gram-positive and gram-negative aerobic and anaerobic micro-organisms (clostridial and non-clostridial in composition with aerobic and facultative anaerobic).
Germs which can be typically treated with Pathelen® are:
Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), Enterobacteria i.e. – Escherichia coli – Klebsiella pneumoniae – Klebsiella oxytoca, Proteus mirabilis, Non-fermenting organisms i.e. Pseudomonas aeruginosa – Acinetobacter baumannii – Pseudomonas and more
Clinical practice shows that the current, individual use of other antimicrobial agents in the treatment of purulo-inflammatory diseases and purulent wounds, does not always lead to the desired result. Additionally, misuse of antibiotics has contributed to the emergence of resistant (hospital) strains of pathogenic micro-organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and become a serious challenge for modern medicine.
Pathelen® can solve this problem, utilising new compositions based on highly dispersed silicas and which have enhanced absorptive, anti-inflammatory and wound-healing abilities for the treatment of a wide range of diseases caused by pathogenic micro-organisms, in particular, purulent wounds.
The intensity of the regeneration process and healing of infected ulcers and wounds depends largely on the speed with which they are cleared of pus and necrotic tissues. Applique sorption, a method of wound healing in which an absorbent in powder form is applied to the wound as a dressing, greatly accelerates this process. This absorption detoxification restores the integrity of the skin and mucous membranes by the removal of microbial cells, bacterial toxins and toxic metabolites of wound fluid and wound cavities in direct contact with the surface of Pathelen®.
Another important therapeutic factor in the first phase of wound healing is dehydration, i.e. absorption of fluid from the wound cavity and perifocal tissues. Hydrophilic highly dispersed silica (HDS) can be used in the first phase of wound healing. Its detoxifying action is due to the absorption of pathogenic protein substances (up to 800 mg/g), including microbial enzymes, exo- and endotoxins (Lipopolysaccharides) and micro-organisms.
Pathelen® is a pioneering new treatment for a wide range of wounds in soft tissues with aerobic and anaerobic infections, for previously incurable wounds and for common chronic wound diseases including:
Chronic pressure ulcers
Venous leg ulcers
Fungating, cancerous or malignant lesions and wounds with necrotic tissue
Pathelen® can prevent bacterial infections in post-op wound treatment and has haemostatic action (a process which causes bleeding to stop).
Some strains of MRSA are resistant to all kinds of antibiotics. Pathelen®, due to its affinity to proteins, heals uniquely by agglutinating (clumping together) microorganisms which have protein molecules on the surface.
Through its revolutionary strategy, a local physical absorption treatment of wound bacteria is used instead of the traditional approach of a systemic antibiotic treatment. Pathelen® can even successfully treat ongoing, irreparable wound infections, which are "protected" by a biofilm, or wounds which are contaminated with antibiotic resistant MRSA and extended spectrum beta lactamases (ESBL) producing bacteria like E. coli and Klebsiella.
The most typical problems of patients with these wounds are:
Rapid destruction of tissue
Slow detersion of a wound
Increase of infectious and inflammatory process (SIRS, sepsis)
The unique effect of Pathelen is achieved through various simultaneous mechanisms:
Helps elimination of the biofilm
Sorption of necrotic tissues
Sorption of pus and toxins (including large amounts of problematic lipopolysaccharides)
Preparation of a physiological wound environment with granulating tissue
% FDA-CODE CAS No Function
64% A2C 7631-86-9 Active Substance
Aerosil R972 Pharma
35.9% 68 611-44-9 Active Substance
0.1% 63449-41-2 Surfactant
Rapidly removes toxins from any wound and heals it
Bacteria can’t develop resistance
Blocks corrosive properties of saliva and lymph
Very high sorption and does not penetrate the blood circle
Removes bacteria and prevents it from re-entering the wound
Efficiently eliminates the multi-resistant bacteria flora
Destroys micro-organism optimal living conditions
Inhibits surface and intracavitary bleeding
Reduces risk of sepsis and considerably reduces infection
Decreases exotoxins production
Can be used with other medicines and has no known side effects
Easy to store and use requires minimal training